Plain-English translation of NCT04185038 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called B7-H3-specific CAR T cells for children and young adults with difficult-to-treat brain tumors. Doctors take your own immune cells, engineer them in the lab to recognize and attack cancer cells, and then deliver them directly into your brain through a small catheter. The goal is to help your immune system fight the tumor more effectively.
Brain tumors like DIPG (diffuse intrinsic pontine glioma) and other pediatric brain cancers are very hard to treat and often come back after standard therapy. This treatment aims to offer a new option by using your own immune system to target these aggressive tumors.
You likely qualify if…
You likely don't qualify if…
Your own immune cells will be collected and sent to the lab to be engineered. Once ready, the treatment cells are delivered through your brain catheter in two courses: either weekly doses for three weeks (with a break and check-up in between) or every-other-week doses, depending on your tumor type. You will have regular examinations and imaging scans to monitor how you respond, and you will be followed for at least 15 years after treatment to track your long-term health.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States